Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2014 08:30 ET | Source: NovaBay Pharmaceuticals, Inc.

Dr. John Crew Gives Grand Rounds Presentation on Treating Wounds With NovaBay's NeutroPhase at Eisenhower Medical Center

Dr. Crew Describes How His Breakthrough Treatment Using NeutroPhase is Saving the Lives and Limbs of Patients With Deadly 'Flesh-eating Disease' EMERYVILLE, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE)...
February 03, 2014 08:30 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals to Present at BIO CEO & Investor Conference

EMERYVILLE, Calif., Feb. 3, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial...
January 28, 2014 08:30 ET | Source: NovaBay Pharmaceuticals, Inc.

Research Breakthrough for Deadly Flesh-Eating Disease Reported in the Journal Cell Highlights Importance of Neutralization of Toxins Associated With Flesh-Eating Bacteria

http://www.jpost.com/Health-and-Science/Hebrew-University-researchers-explain-how-innocent-bacteria-can-cause-flesh-eating-disease-338459 EMERYVILLE, Calif., Jan. 28, 2014 (GLOBE NEWSWIRE) --...
January 09, 2014 08:30 ET | Source: NovaBay Pharmaceuticals, Inc.

Photo Release -- NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek, Solta Medical Chairman and CEO and Dr. Massimo Radaelli, Noventia Pharma CEO to Its Board of Directors

Combined Total of Over 50 Years of Healthcare Experience in Global Markets Adds Significant Depth to NovaBay's Board EMERYVILLE, Calif., Jan. 9 2014 (GLOBE NEWSWIRE) -- NovaBay®...
January 08, 2014 08:30 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Provides Business Unit Update and 2014 Outlook

Urology Reported Positive Phase 2 Clinical Study Results of Auriclosene to Reduce Urinary Catheter Blockage and Encrustation (UCBE) Ophthalmology Completion of Global Conjunctivitis Clinical...
December 19, 2013 08:00 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Announces Plan to Reinitiate Clinical Evaluation of Auriclosene for Impetigo in 2014

Impetigo Clinical Program Moves Forward With Optimized Formulation EMERYVILLE, Calif., Dec. 19, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage...
December 12, 2013 08:30 ET | Source: NovaBay Pharmaceuticals, Inc.

Dr. Ron Najafi, CEO of NovaBay Pharmaceuticals, Urges FDA to Formally Ban Antibiotic Use in Food Production

FDA's Recently Announced Plan to Curb Antibiotic Use in Animals is Merely Voluntary and Should go Further NovaBay Calls for Labeling of Antibiotic-fed Meats EMERYVILLE, Calif., Dec. 12, 2013...
December 11, 2013 08:30 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Gains ISO 13485 Certification for the Design and Manufacturing of NeutroPhase(R)

Company Meets Internationally Recognized Quality and Regulatory Standards EMERYVILLE, Calif., Dec. 11, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage...
December 02, 2013 09:02 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals and China Pioneer Pharma Announce Expansion of Partnership Agreement

Pioneer to License Rights to Commercialize Two New NovaBay Products In China and Southeast Asia NovaBay to Receive $5.7 Million Equity Investment from China Pioneer Pharma EMERYVILLE, Calif.,...
November 14, 2013 09:20 ET | Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Reports Third Quarter 2013 Financial Results and a Clinical/Business Update

Phase 2b study of Auriclosene for Impetigo Completed by Partner Galderma Reported Positive Results from Phase 2 Clinical Study of Auriclosene to Reduce Urinary Catheter Blockage and Encrustation...